Among the available PSMA ligands, the majority of safety data stems from clinical trials on prostate cancer treatment using [177Lu]Lu-PSMA-617, including the phase III VISION trial and phase II studies such as TheraP and RESIST-PC [71,72,73]. Here, FOLH1 is linked to prostate carcinoma.